Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

PPPI-III conference to focus on fundamental research and industrial application of particulate processing

Over 80% of all pharmaceutical products are in the solid dosage form. Particulate processes therefore abound in the pharmaceutical industry. These include crystallization; drying, granulation, and coating; tablet compaction; fine powder transport, mixing, and blending. These and other particulate processes are used for the large-scale manufacture of tablets and capsules as well as dry powder inhalants for public consumption.

13 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

Wanxin Optical, Essilor enter joint venture agreement to broaden product range in Chinese market

Essilor International has announced it is taking a 50% stake in Wanxin Optical, one of China's leading manufacturers of ophthalmic lenses, as part of a joint venture agreement.

13 Jan 2011

CE mark approves Vitrolife's SpermFreeze Solution

SpermFreeze Solution, which is used for freeze storage of sperm, has obtained a CE mark and is thereby approved for sales within the European Economic Area.

12 Jan 2011

Intertek announces acquisition of American Analytical Chemistry Laboratories

Intertek, a leading provider of quality and safety solutions serving a wide range of industries around the world, has acquired American Analytical Chemistry Laboratories Corp (AACL), a testing, analytics and research company focusing on food, functional foods, nutritional supplements, cosmeceuticals and pharmaceuticals.

12 Jan 2011

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.

11 Jan 2011

HITRUST designates PwC as a Common Security Framework Assessor

PwC US announced today that the Health Information Trust Alliance (HITRUST) has designated the firm a Common Security Framework (CSF) Assessor, qualified to evaluate and certify security standards of CSF-related services.

11 Jan 2011

Mithridion secures commitments of $1.25 million in new funding

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease, announces that it has secured commitments of $1.25 million in new funding.

11 Jan 2011

PakSense launches new class of temperature monitoring device

PakSense, an innovator in sensory solutions for packaging, announced today the launch of the PakSense BIOmed Label product line for use in clinical trials, pharmaceuticals, biologics, vaccines and other healthcare-related material transport.

11 Jan 2011

BiAqua, DSM enter partnership for strain and process development of BiAqua Ferritin

DSM BioSolutions, Royal DSM's microbial fermentation contract manufacturing business, and BiAqua B.V., an innovator in delivering bio-based solutions for serious water contamination issues, today announced that they have entered into an agreement for strain development, process development and production of "BiAqua Ferritin" for BiAqua's core technology to address bio-fouling and arsenic contamination in the water sector.

11 Jan 2011

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.

11 Jan 2011

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.

11 Jan 2011

IGI Laboratories submits second abbreviated new drug application to FDA

IGI Laboratories, a New Jersey based formulation and manufacturing company, today announced that it has submitted its second abbreviated new drug application to the US FDA.

10 Jan 2011

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma, today announced that it has successfully completed a Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in juveniles with hypophosphatasia, a serious, rare metabolic bone disorder.

10 Jan 2011

Bonso reports $0.27 million net income for half year ended September 30, 2010

Bonso Electronics International, Inc. today reported its financial results for the six-month period ended September 30, 2010.

10 Jan 2011

Emergent BioSolutions estimates total revenue of $285 to $288 million for 2010

Emergent BioSolutions Inc. announced today preliminary, unaudited financial results for 2010 and guidance for 2011.

10 Jan 2011

Civitas receives $20 million Series A financing

Civitas Therapeutics, Inc., a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies, announced today that it has secured a $20 million Series A financing from founding investor, Longitude Capital, along with co-lead Canaan Partners. The proceeds of the financing will be primarily used to advance Civitas' lead program for treating patients with Parkinson's disease through clinical proof-of-concept.

10 Jan 2011

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

Amsterdam Molecular Therapeutics, a leader in human gene therapy, announced today that it has entered into an agreement with Institut Pasteur, Paris, France, and a group of French research institutes (together the "Consortium") to support clinical development of a novel gene therapy to treat Sanfilippo B.

10 Jan 2011

New lab-on-a-chip technology detects protein in blood less than 30 minutes

While most blood tests require shipping a vial of blood to a laboratory for analysis and waiting several days for the results, a new device invented by a team of engineers and students at the University of Rhode Island uses just a pinprick of blood in a portable device that provides results in less than 30 minutes.

10 Jan 2011

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

Manufacturing News and Research

Further Reading

PPPI-III conference to focus on fundamental research and industrial application of particulate processing

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

Wanxin Optical, Essilor enter joint venture agreement to broaden product range in Chinese market

CE mark approves Vitrolife's SpermFreeze Solution

Intertek announces acquisition of American Analytical Chemistry Laboratories

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

HITRUST designates PwC as a Common Security Framework Assessor

Mithridion secures commitments of $1.25 million in new funding

PakSense launches new class of temperature monitoring device

BiAqua, DSM enter partnership for strain and process development of BiAqua Ferritin

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

IGI Laboratories submits second abbreviated new drug application to FDA

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Bonso reports $0.27 million net income for half year ended September 30, 2010

Emergent BioSolutions estimates total revenue of $285 to $288 million for 2010

Civitas receives $20 million Series A financing

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

New lab-on-a-chip technology detects protein in blood less than 30 minutes

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy